| Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients M Cicala, M Gori, P Balestrieri, A Altomare, A Tullio, S Di Cola, S Dejongh, ... International Journal of Molecular Sciences 25 (11), 5817, 2024 | | 2024 |
| T. 04.2: THE NEGLECTED PROBLEM OF NON-ADHERENCE TO ORAL MESALAMINE MAINTENANCE THERAPY IN ULCERATIVE COLITIS PATIENTS: LITERATURE SYSTEMATIC REVIEW AND RESULTS FROM A … C Pagnini, E Antonelli, G Mocci, M Cappello, B Scrivo, M Soncini, ... Digestive and Liver Disease 56, S236-S237, 2024 | | 2024 |
| Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter … A Tursi, G Mocci, L Allegretta, G Aragona, MA Bianco, R Colucci, ... INFLAMMATORY BOWEL DISEASES, 2024 | 1 | 2024 |
| Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study A Tursi, G Mocci, L Cingolani, E Savarino, R Pica, A Cocco, M Zippi, ... Expert Opinion on Pharmacotherapy 24 (14), 1649-1656, 2023 | 2 | 2023 |
| Probiotics in COVID-19 pandemic: When evidence lacks, rationale can still ease the way C Pagnini, MCDI Paolo, L D'alba, R Urgesi, L Pallotta, G Villotti, ... Minerva gastroenterology 69 (2), 314-317, 2023 | 2 | 2023 |
| Safety and Potential Role of Lactobacillus rhamnosus GG Administration as Monotherapy in Ulcerative Colitis Patients with Mild–Moderate Clinical Activity C Pagnini, MC Di Paolo, R Urgesi, L Pallotta, G Fanello, MG Graziani, ... Microorganisms 11 (6), 1381, 2023 | 1 | 2023 |
| Application of validated bleeding risk scores for atrial fibrillation in obscure gastrointestinal bleeding patients increases videocapsule endoscopy’s diagnostic yield: a … R Urgesi, C Pagnini, F De Angelis, MC Di Paolo, L Pallotta, G Fanello, ... International Journal of Colorectal Disease 38 (1), 120, 2023 | 1 | 2023 |
| Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study G Mocci, A Tursi, G Maconi, G Cataletti, B Mantia, M Serio, A Scarcelli, ... Expert Opinion on Biological Therapy 23 (3), 293-304, 2023 | 3 | 2023 |
| T. 06.8 REAL WORD LONG-TERM EFFICACY AND SAFETY OF VEDOLIZUMAB IN MANAGING ULCERATIVE COLITIS VERSUS CROHN'S DISEASE: RESULTS FROM “LONG VEDO” ITALIAN MULTICENTER STUDY G Mocci, G Maconi, G Cataletti, B Mantia, M Serio, A Scarcelli, FM Onidi, ... Digestive and Liver Disease 55, S162-S163, 2023 | | 2023 |
| Comparison of performances of adalimumab biosimilars SB5, ABP501, GP2017, and MSB11022 in treating patients with inflammatory bowel diseases: a real-life, multicenter … A Tursi, G Mocci, L Allegretta, G Aragona, MA Bianco, R Colucci, ... Inflammatory Bowel Diseases 29 (3), 376-383, 2023 | 14* | 2023 |
| P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from “long vedo” italian multicenter study G Mocci, G Maconi, FM Onidi, G Cataletti, W Elisei, F Scaldaferri, ... Journal of Crohn's and Colitis 17 (Supplement_1), i635-i636, 2023 | | 2023 |
| Replacement of adalimumab originator to adalimumab biosimilar for a non-medical reason in patients with inflammatory bowel disease: a real-life comparison of adalimumab … A Tursi, G Mocci, A Cuomo, A Ferronato, W Elisei, M Picchio, G Maconi, ... Journal of Gastrointestinal and Liver Diseases 31 (4), 411-416, 2022 | 7 | 2022 |
| Evaluation of Accuracy and Feasibility of a New-Generation Ultra-Rapid Urease Test for Detection of Helicobacter pylori Infection M Cagnoni, C Pagnini, M Crovaro, A Aucello, R Urgesi, L Pallotta, ... Gastrointestinal Disorders 4 (3), 205-213, 2022 | 2 | 2022 |
| Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study G Mocci, G Bodini, L Allegretta, AI Cazzato, S Chiri, G Aragona, P Perazzo, ... Biomedicines 10 (8), 1799, 2022 | 5 | 2022 |
| Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy A Tursi, G Mocci, L Allegretta, G Aragona, MA Bianco, R Colucci, ... Expert Opinion on Biological Therapy 22 (2), 313-320, 2022 | 1 | 2022 |
| Probiotics and vitamin D/vitamin D receptor pathway interaction: potential therapeutic implications in inflammatory bowel disease C Pagnini, MC Di Paolo, MG Graziani, G Delle Fave Frontiers in Pharmacology 12, 747856, 2021 | 8 | 2021 |
| Tumor necrosis factor’s pathway in Crohn’s disease: potential for intervention C Pagnini, F Cominelli International journal of molecular sciences 22 (19), 10273, 2021 | 14 | 2021 |
| AF. 65 SAFETY AND EFFICACY OF INFLIXIMAB BIOSIMILARS CT-P13 AND SB2, INCLUDING NON MEDICAL SWITCH: A SINGLE CENTER REALLIFE STUDY C Pagnini, MC Di Paolo, A Vignone, D Bellafante, S Fonte, L D’Alba, ... Digestive and Liver Disease 53, S166-S167, 2021 | | 2021 |
| AF. 162 ESOPHAGEAL ACHALASIA: SUCCESSFUL MULTIDISCIPLINARY APPROACH IN DIAGNOSIS AND THERAPEUTIC MINIMALLY INVASIVE ROBOTIC SURGERY L D’Alba, G Pernazza, E Valenzi, MC Di Paolo, C Pagnini, L Pallotta, ... Digestive and Liver Disease 53, S209, 2021 | | 2021 |
| Corticosteroids in Inflammatory Bowel Disease patients: A practical guide for physicians MC Di Paolo, C Pagnini, MG Graziani Current Reviews in Clinical and Experimental Pharmacology Formerly Current …, 2021 | 4 | 2021 |
